Application of a Tissue-Free Epigenomic Assay to Improve MRD Detection in Previously Treated CRC - Episode 3

COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS

October 14, 2024

Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study demonstrated statistically significant recurrence-free intervals across various postoperative and adjuvant chemotherapy time points, highlighting the prognostic value of serial, tissue-free ctDNA assays for real-time detection of MRD vs single postchemotherapy assessments.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Risk of Recurrent Colorectal Cancer Following Definitive Therapy

EP. 2: COSMOS-CRC-01: Study Design and Methodology

Now Viewing

EP. 3: COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS

EP. 4: COSMOS-CRC-01: Sensitivity and Specificity of a Serial, Cell-Free DNA Epigenomic Platform in Detecting MRD in Real Time

EP. 5: Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRC

1. Please summarize the statistically significant recurrence-free intervals across the postoperative, post-ACT, and paired pre- and post-ACT analyses in the COSMOS-CRC-01 study.

2. Please address the prognostic value of serial, tissue-free, epigenomic ctDNA assays in detecting MRD in real time vs a single postchemotherapy time point.